Search

1 to 10 of 67
Sort by

Library Entry
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequencies or characteristics of tumor-reactive, mutation-specific CD8+ T cells could be used...




Library Entry
Lung Cancer Living Room™ - Spanish Edition - A Resource from the GO2 Foundation for Lung Cancer

Every month the GO 2 Foundation for Lung Cancer presents their "Lung Cancer Living Room™" a patient education and support series created for patients and their families. Through presentations by lung cancer specialists, physicians, and researchers, this unrestricted, relaxed forum covers all...


Library Entry
Lung Cancer Living Room™ - Chinese Edition - A Resource from the GO2 Foundation for Lung Cancer

Every month the GO 2 Foundation for Lung Cancer presents their "Lung Cancer Living Room™" a patient education and support series created for patients and their families. Through presentations by lung cancer specialists, physicians, and researchers, this unrestricted, relaxed forum covers all...


Library Entry
Lung Cancer Living Room™ - A Resource from the GO2 Foundation for Lung Cancer

Every month the GO 2 Foundation for Lung Cancer presents their "Lung Cancer Living Room™" a patient education and support series created for patients and their families. Through presentations by lung cancer specialists, physicians, and researchers, this unrestricted, relaxed forum covers all...


Library Entry
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation in primary rather than metastatic sites...




Library Entry
Treatment Option for Squamous Cell Lung Cancer (from LUNGevity)

There are numerous treatment options available to people diagnosed with squamous cell lung cancer, and doctors are working hard to develop and improve these treatments. This website can help you: Learn about squamous cell lung cancer Understand the treatment options available for squamous...